The prophylactic effect of oral hydroxy-chloroquine in close contacts of COVID-19 patients

Phase 3

Recruiting

Conditions: Covid19.
Coronavirus infection, unspecified
B34.2

Registration Number: IRCT20200513047426N1

Lead Sponsor: Boushehr University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 500

Inclusion Criteria

Close contact with a person with COVID-19 who has been diagnosed positive with a definitive test.
Close contact: contact, hand shake and talking at least once in the last 2 days for less than 2 meters with COVID-19 patient who have been diagnosed positive with a definitive test.
Family, friends, relatives who have been in the same place for a period of 4 hours or more in the last 2 days with a COVID-19 patient who have been diagnosed with a definitive test .
Medical staff, including physicians, nurses, midwives, and service personnel which have been in contact with COVID-19 patient who has been diagnosed with a definitive test in the past three days.

Exclusion Criteria

Lack of satisfaction from entered persons
The presence of diseases or conditions in which the use of hydroxychloroquine is as a contraindication, such as patients with heart failure who take QT prolonging drugs are as contraindications.
Existence of distorting factors during the implementation of clinical trial.+ During the study, people should be in home quarantine . + Do not Excessive use of vitamins and medications.+ has Meals like family’s.+has Regular sleep cycle
Complications of hydroxychloroquine based on the Iranian rheumatology association include the following:1- Nausea, decreased appetite and diarrhea 2- Skin allergies 3- Skin discoloration 4- Ocular sensitivity 5- Headache 6- Rush

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Percentage of people who have not been diagnosed with Covid19 after co-administration of hydroxychloroquine. Timepoint: The end of study. Method of measurement: Diagnostic COVID-19 Kits.

Secondary Outcome Measures